On 1 April 2019 orphan designation (EU/3/19/2146) was granted by the European Commission to Taiho Pharma Europe Limited, United Kingdom, for 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]-2-propen-1-one (also known as TAS-120) for the treatment of biliary tract cancer.

Key facts

Active substance
1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]- 1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]-2-propen-1-one
Disease / condition
Treatment of biliary tract cancer
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Taiho Pharma Europe Limited
11th Floor
Two Snowhill
Snow Hill Queensway
Birmingham B4 6WR
United Kingdom
Tel: +1 609 250 7292

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating